# A 10-year update to the principles for clinical trial data sharing by pharmaceutical companies: perspectives based on a decade of literature and policies.

- **DOI:** [10.1186/s12916-023-03113-0](https://doi.org/10.1186/s12916-023-03113-0)
- **Rating:** Sound (3.3 out of 5)
- **Verdict:** An actionable update to industry data-sharing principles that consolidates a decade of policy development, but lacks a transparent source-selection method.
- **Framework version:** v5.9
- **Pipeline version:** v0.4
- **Evaluation date:** 2026-09-28
- **Evaluation page:** https://www.nabu.science/paper/10.1186%2Fs12916-023-03113-0

## Key claims

Key claims could not be produced for this evaluation. The rest of the evaluation is unaffected.

## Strengths

- **Operational policy framework with clear timelines** Table 1 specifies which materials should be shared, proposed timing, governance arrangements, supporting documentation, and public-policy formats. This moves beyond a general endorsement of transparency toward language that policy teams could adapt.
  - Dimension: contribution
  - Location: Enhancing Data Sharing Practices, Table 1
- **Traceable issue-to-recommendation structure** Each major section begins from an established policy position, describes subsequent developments, and connects them to a proposed update. The six-part structure mirrors Table 1 and keeps the argument legible.
  - Dimension: reporting
  - Location: Participant-Level Data Sharing through Public Data Sharing Policies; Table 1
- **Visible pathway to policy use** The article names pharmaceutical companies, PhRMA/EFPIA, regulators, review panels, sponsors, and sharing platforms as relevant actors. Its proposed public registers, timelines, and standardised policy formats give those actors concrete points of intervention.
  - Dimension: application pathway
  - Location: Progress and Challenges in Clinical Trial Data Sharing; Table 1; Conclusions

## Limitations

- **Source-selection method remains unreported** The article states that it draws on a decade of literature and reported experience but provides no search strategy, inclusion criteria, coverage dates, or appraisal process. This limits confidence in the completeness and balance of the synthesis.
  - Dimension: methodological rigour
  - Location: Enhancing Data Sharing Practices, paragraph 1
- **Implementation trade-offs receive limited adjudication** Privacy, consent, security, regulator resources, and fragmentation are acknowledged, but their consequences for individual recommendations are not systematically traced. This leaves the feasibility and achievability claims less secure than the policy rationale.
  - Dimension: positioning
  - Location: Participant-Level Data Sharing; Sharing of Clinical Study Reports; Future Directions; Conclusions
- **Recommendations lack adoption evidence** The paper offers no pilot, company-level implementation case, outcome evaluation, or sequencing plan for the proposed package. Its translation pathway therefore remains at the policy-framework stage.
  - Dimension: application pathway
  - Location: Table 1; Future Directions; Conclusions

## Reliability checks

No concerns (4 of 4 checks).

- **Internal coherence:** Clean. The recommendations in Table 1 align with the accompanying sections, and empirical figures are presented as findings from cited investigations rather than original analyses. No internal contradiction or material language–evidence mismatch was identified.
- **Research conduct:** Clean. The article reports no new human-participant research, statistical analysis, or original dataset requiring ethics approval, registration, or availability materials. Funding and conflict-of-interest declarations were not visible in the supplied text, but that absence does not establish a conduct concern for this perspective article.
- **Reference integrity:** Clean. 44 of 44 checkable references verified
  - 74 references in manuscript
  - 30 have no canonical index record — counted, but not index-checkable
  - citation details diverge from the cited records for 1 reference
  - 3 references confirmed by manual review
  - Citation details diverge for 1 reference:
    - #41 Egilman AC Ross JS Herder M Optimizing the data available via Health Canada’s clinical information portal CMAJ 2021 193 33 E1305 e6 34426449 10.1503/cmaj.210877 PMC8412426 (Differs from the cited DOI’s record on: container, authors)
  - References not verified automatically are resolved manually within 24 hours.

## Post-publication record

- **Status:** Clean
- **Summary:** No retraction or expression of concern found in Crossref (includes Retraction Watch).
- **Last checked:** 2026-10-17
